United Kingdom

People: Atrion Corp (ATRI.OQ)

ATRI.OQ on NASDAQ Stock Exchange Global Select Market

18 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Spaulding, Ronald 

Mr. Ronald Nicholas Spaulding is Independent Director of Atrion Corporation. He has been a director since February 2006 and has been a private investor since 2008. Prior to May 2008, Mr. Spaulding was the President of Worldwide Commercial Operations of Abbott Vascular and a Vice President and corporate officer of Abbott Laboratories, which he joined in April 2006 upon its acquisition of Guidant Corporation’s vascular intervention assets. Between 2005 and April 2006, Mr. Spaulding served as the President of International Operations of Guidant Corporation, a medical device manufacturer, and also served on the Guidant Management Committee from 2002 until 2005. From 2003 to 2005, he was the President of Europe, Middle East, Africa and Canada of Guidant Corporation. From 2000 to 2003, Mr. Spaulding served as President of Guidant Corporation’s cardiac surgery business. Mr. Spaulding holds a Master’s degree in Biomedical Engineering and a Bachelor of Science degree in Mechanical Engineering from the University of Miami. Mr. Spaulding’s over 21 years of healthcare experience, including service as an officer of publicly-held companies with medical device operations, his knowledge of regulatory and operational matters affecting the development and marketing of medical devices, and his educational background enable Mr. Spaulding to bring a valuable and unique perspective to our Board.

Basic Compensation

Total Annual Compensation, USD 70,000
Restricted Stock Award, USD 60,000
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 130,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Emile Battat


David Battat


Jeffery Strickland


Preston Athey


Hugh Morgan


Ronald Spaulding

As Of  31 Dec 2018